Im
Non vérifié

Imbrium Therapeutics L.P.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté
09/09/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Santé Publique
Industrie
Results From Sunobinop Phase 1B Study in Patients With Interstitial Cystitis/Bladder Pain Syndrome Announced
1.00
16/06/2025
Biotechnologie
Santé
Oncologie
Médecine - Divers
Événements
Imbrium Therapeutics to Showcase Pipeline Assets Open for Partnership at the BIO International Convention 2025
1.00
07/01/2025
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Imbrium Therapeutics Announces Results of a Sunobinop Phase 1b Study in Patients With Overactive Bladder Syndrome
1.00
18/11/2024
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Imbrium Therapeutics Completes First Patient Dosed in Phase 2 Study to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
1.00
05/08/2024
Santé
Hygiène alimentaire
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Imbrium Therapeutics Submits Investigational New Drug Application to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
1.00
09/07/2024
Industrie
Biotechnologie
Industrie pharmaceutique
Santé
Médecine - Divers
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Overactive Bladder Syndrome
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0